Create Medicines Raises $122M Series B to Advance In Vivo CAR Therapies
- May 21
- 1 min read
Cambridge, MA, May 14, 2026 (PR Newswire) -- Create Medicines has secured $122 million in Series B financing to accelerate development of its in vivo CAR-based therapeutic programs. The funding will support pipeline expansion across autoimmune disease and oncology indications. The investment is intended to advance the company’s platform toward clinical-stage development.
Read full article here.






















Comments